Insulet (NASDAQ: PODD) reported Q3 EPS of $0.18, $0.07 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $275.6 million versus the consensus estimate of $272.82 million.

2021 Outlook:

• Revenue Guidance (in constant currency):
• For the year ending December 31, 2021, the Company is updating its revenue growth guidance range to 18% to 20% (previously 16% to 20%). Revenue growth ranges by product line are:
• Total Omnipod of 18% to 20% (previously 18% to 21%)
• U.S. Omnipod of 22% to 24% (previously 22% to 25%)
• International Omnipod of 12% to 14% (previously 11% to 15%)
• Drug Delivery of 11% to 16% (previously (11)% to 4%)
• For the quarter ending December 31, 2021, the Company expects revenue growth of 19% to 25%. Revenue growth ranges by product line are:
• Total Omnipod of 17% to 22%
• U.S. Omnipod of 22% to 27%
• International Omnipod of 7% to 13%
• Drug Delivery of 45% to 65%
• Operating Margin Guidance:
• For the year ending December 31, 2021, the Company is reaffirming its expectations of operating margin in the low double digits range.

For earnings history and earnings-related data on Insulet (PODD) click here.